Skip to content
Home
About Us
Our Goal
Management Team
Board of Directors
Scientific Advisory Board
Technology Platform
The Challenge
Platform
Our Focus
Focus Areas
Pipeline
Osteoporosis
Hypoparathyroidism
Inflammatory Diseases
Strategic Partners
Investors & Media
Contact Us
Menu
Home
About Us
Our Goal
Management Team
Board of Directors
Scientific Advisory Board
Technology Platform
The Challenge
Platform
Our Focus
Focus Areas
Pipeline
Osteoporosis
Hypoparathyroidism
Inflammatory Diseases
Strategic Partners
Investors & Media
Contact Us
Inflammatory
Diseases
Under our 2018 license agreement with Amgen we are developing oral formulations of novel therapeutic protein candidates.
Thank You
Message Sent!
We will get back to you soon